Navigation Links
Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC
Date:5/21/2013

Raleigh, NC (PRWEB) May 21, 2013

Clinverse, Inc., a global technology and financial services company for clinical trials, announced today it has formed a strategic alliance with Aggregate Spend Solutions, LLC. Clinverse’s ClinPay® FLS eClinical commerce platform aggregates data collected through an automated investigator payment process. SpendMD™, Aggregate Spend Solutions’ recently-launched flagship product, is the only complete solution for tracking and reporting transfer of value at investigator meetings or any meeting where healthcare providers (HCPs) receive varying types of compensation from sponsors in exchange for their involvement. Together, the combined solution provides a “one-stop-shop” for the collection of data required by the Sunshine Act, also known as the Physician Payment Sunshine Act (PPSA).

“We are pleased to announce this strategic partnership with SpendMD. Not only are we able to provide our clients with the ability to collect investigator payment data currently generated by ClinPay FLS, but we are now able to automate the acquisition of investigator payment data collected during investigator meetings and other sponsor-related events,” said Steve Ayala, Clinverse President and head of partnerships. “We know that compliance with the Sunshine Act requirements have been, and continue to be, a significant concern for our clients and the industry as a whole. We are investing our resources, time and expertise to develop integrated solutions to address these concerns through the automation of the data collection and reporting process required by CMS.”

ClinPay FLS’ open application programming interface (API) allows for seamless integration with SpendMD, as well as other clinical trial platforms (e.g., EDS, CTMS, and IxRS applications), meeting planning software, or any other electronic systems used to accurately report various direct or indirect payments made to HCPs as required by the new legislation. With the Sunshine Act now requiring the collection of data beginning August 1, 2013, the timing of this partnership benefits clinical trial sponsors looking to gain compliance and provide a comprehensive, automated solution for tracking total investigator spend, both direct and indirect, while alleviating a time-intensive burden from sponsors.

John Lewis, CEO of Aggregate Spend Solutions, stated, “We understand the complexities unique to transfer of value spend capture – working with multiple vendors, meeting-related expenses, and other issues. Our partnership with Clinverse allows us to provide our clients with our expertise and proven technology, while also providing them access to a centralized and scalable aggregate spend solution anchored by Clinverse’s proven investigator payment platform. We look forward to working with Clinverse and continuing to provide our clients with all of the services and technology required to meet the Sunshine Act reporting requirements that are looming.”

About Aggregate Spend Solutions, LLC

Aggregate Spend Solutions, LLC was formed as a result of the new and stringent reporting requirements of the Physicians Payment Sunshine Act. SpendMD™, sunshine tracking and reporting is the organization’s key software product that provides the Health and Life Science Industries with the only complete solution for tracking and reporting “indirect spend” for HCP Meetings. Based in Raleigh, North Carolina with global development centers, Aggregate Spend Solutions is a key leader in the design, development, implementation and support of data aggregation products and services. For more information, please visit http://www.spendmd.com.

About Clinverse, Inc.

Clinverse, Inc. is a global technology and financial services company that delivers highly secure, cloud-based financial management and payment solutions for the clinical trials industry. Founded in 2008 and headquartered in Raleigh, NC, the company delivers clinical financial solutions through the only truly collaborative and transparent financial management and payment platform. Used by leading BioPharma companies, Clinverse has developed ClinPay® FLS, a fully-configurable, game-changing SaaS-based platform which manages tens of millions of dollars in financial transactions for thousands of Global sites while supporting payments in 140 different currencies. For more information, please visit http://www.clinverse.com.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10751165.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
3. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
5. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
6. WuXi PharmaTech Announces Third-Quarter 2011 Results
7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
8. Spherix Announces Third Quarter Financial Results
9. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
10. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
11. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. Hays ... DNA as a Field Application Specialist. , “I am thrilled that Dr. Young ... DNA. “In further expanding our capacity as a scientific integrator, Hays brings a wealth ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
Breaking Biology Technology:
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... project, for the , Supply and Delivery of ... Infrastructure , to Decatur , ... Management Solutions. Numerous renowned international vendors participated in the tendering ... selected for the most compliant and innovative solution. The contract ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled ... medical LCD display is the latest premium product recently added to the range of ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
Breaking Biology News(10 mins):